Roth Capital reiterated their buy rating on shares of Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) in a research report released on Friday. Roth Capital currently has a $2.50 price target on the biopharmaceutical company’s stock.
CPRX has been the topic of a number of other research reports. Zacks Investment Research raised Catalyst Pharmaceutical Partners from a hold rating to a buy rating and set a $1.00 target price on the stock in a research note on Tuesday, June 21st. Piper Jaffray Cos. upgraded Catalyst Pharmaceutical Partners from a neutral rating to an overweight rating and set a $4.00 price target for the company in a report on Wednesday, October 5th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $3.38.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) traded up 2.22% on Friday, reaching $1.38. The company had a trading volume of 215,642 shares. The company’s market capitalization is $114.36 million. Catalyst Pharmaceutical Partners has a 52 week low of $0.51 and a 52 week high of $3.55. The stock’s 50-day moving average is $1.13 and its 200-day moving average is $0.89.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. Equities research analysts forecast that Catalyst Pharmaceutical Partners will post ($0.25) EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP purchased a new stake in shares of Catalyst Pharmaceutical Partners during the second quarter worth about $440,000. Paloma Partners Management Co bought a new stake in Catalyst Pharmaceutical Partners during the second quarter worth $200,000. DRW Securities LLC bought a new stake in Catalyst Pharmaceutical Partners during the second quarter worth $168,000. Renaissance Technologies LLC bought a new stake in Catalyst Pharmaceutical Partners during the first quarter worth $206,000. Finally, Royal Bank of Canada bought a new stake in Catalyst Pharmaceutical Partners during the second quarter worth $117,000. Hedge funds and other institutional investors own 30.64% of the company’s stock.
Catalyst Pharmaceutical Partners Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceutical Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceutical Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.